-
公开(公告)号：US20240197708A1
公开(公告)日：2024-06-20
申请号：US18553758
申请日：2022-04-14
Applicant: Prilenia Neurotherapeutics Ltd.
Inventor： Michael HAYDEN , Michal GEVA
IPC: A61K31/451 , A61P25/14 , A61P25/28
CPC classification number: A61K31/451 , A61P25/14 , A61P25/28
Abstract: Disclosed herein are methods treating prodromal HD in a subject, wherein the subject has at least 36 CAG repeats in the huntingtin (Htt) gene, wherein the method comprises administering a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240148708A1
公开(公告)日：2024-05-09
申请号：US18416210
申请日：2024-01-18
Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
Inventor： Michael HAYDEN , Michal GEVA
IPC: A61K31/4418 , A61P25/28
CPC classification number: A61K31/4418 , A61P25/28
Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine or pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240050423A1
公开(公告)日：2024-02-15
申请号：US18489863
申请日：2023-10-19
Applicant: Prilenia Neurotherapeutics Ltd.
Inventor： Michael HAYDEN , Mahmoud Abdulhossein Pouladi
IPC: A61K31/4453 , A61K9/00 , A61P25/22 , A61K9/48 , A61P25/24
CPC classification number: A61K31/4453 , A61K9/0053 , A61P25/22 , A61K9/48 , A61P25/24
Abstract: The invention provides a method of reducing anxiety and/or depression in a subject comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to reduce anxiety and/or depression in a subject.
-
公开(公告)号：US20230390272A1
公开(公告)日：2023-12-07
申请号：US18249548
申请日：2021-10-20
Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
Inventor： Michael HAYDEN , Michal GEVA
IPC: A61K31/451 , A61K31/444 , A61P25/22 , A61P25/24 , A61P25/28
CPC classification number: A61K31/451 , A61K31/444 , A61P25/22 , A61P25/24 , A61P25/28
Abstract: The invention provides a method of reducing anxiety and/or depression in a subject comprising administering to the subject a pharmaceutical composition comprising pridopidine or pharmaceutical acceptable salts and at least one of compounds 1-8 or pharmaceutical acceptable salt thereof described herein, effective to reduce anxiety and/or depression in a subject.
-
公开(公告)号：US20210106572A1
公开(公告)日：2021-04-15
申请号：US16952123
申请日：2020-11-19
Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
Inventor： Michal GEVA , Ralph LAUFER , Michael HAYDEN
IPC: A61K31/451 , A61P25/14 , A61K9/00
Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.
-
Patent Agency Ranking
公开(公告)号：US20250082619A1
公开(公告)日：2025-03-13
申请号：US18950102
申请日：2024-11-17
Applicant: Prilenia Neurotherapeutics Ltd.
Inventor： Michael HAYDEN , Michal GEVA
Abstract: Provided herein a method of maintaining, improving, or lessening the decline of functional capacity, cognition, motor function, disease progression and quality of life of a subject afflicted with Huntington disease, including those afflicted with early-stage Huntington disease (HD1 and HD2, TFC 7-13) by orally administering to the subject a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240261273A1
公开(公告)日：2024-08-08
申请号：US18630030
申请日：2024-04-09
Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
Inventor： Michael HAYDEN , Michal GEVA
IPC: A61K31/451 , A61P25/28 , A61P27/06
CPC classification number: A61K31/451 , A61P25/28 , A61P27/06
Abstract: This application provides a composition comprising pridopidine or pharmaceutically acceptable salt thereof and at least one of compounds 1-8 (described herein) or pharmaceutically acceptable salt thereof for use in the treatment of neurodegenerative eye disease, symptoms thereof, and additional neurodegenerative disorders.
-
公开(公告)号：US20240075021A1
公开(公告)日：2024-03-07
申请号：US18489846
申请日：2023-10-19
Applicant: Prilenia Neurotherapeutics Ltd.
Inventor： Michael HAYDEN , Spyridon PAPAPETROPOULOS , Juha-Matti SAVOLA , Eli EYAL , Beth BOROWSKY , Igor D. GRACHEV , Mark Forrest GORDON
IPC: A61K31/451 , A61K9/00 , A61P21/00
CPC classification number: A61K31/451 , A61K9/0053 , A61P21/00
Abstract: The invention provides a method of treating a subject afflicted with a dystonia, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
-
公开(公告)号：US20230414596A1
公开(公告)日：2023-12-28
申请号：US18253221
申请日：2021-11-19
Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
Inventor： Michael HAYDEN , Michal GEVA
IPC: A61K31/451 , A61K31/4418 , A61K31/4545 , A61P25/00
CPC classification number: A61K31/451 , A61K31/4418 , A61K31/4545 , A61P25/00
Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject a pharmaceutical composition comprising pridopidine or pharmaceutical acceptable salts and at least one of compounds or pharmaceutical acceptable salt thereof disclosed herein, so as to thereby treat the subject.
-
公开(公告)号：US20230355595A1
公开(公告)日：2023-11-09
申请号：US18324980
申请日：2023-05-28
Applicant: Prilenia Neurotherapeutics Ltd.
Inventor： Michael HAYDEN , Michal GEVA
Abstract: Provided herein a method of maintaining, improving, or lessening the decline of functional capacity, cognition, motor function and quality of life of a subject afflicted with Huntington disease, including those afflicted with early-stage Huntington disease (HD1 and HD2, TFC 7-13) by orally administering to the subject a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.018 seconds)
